Get started
Work

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial

Year: 2025
Type: conference-abstract
Source: Blood
DOI: 10.1182/blood-2025-792
Authors: Valeria Santini, Matteo Della Porta, Rami Komrokji, Veronika Pozharskaya, Thalia Farazi, Karen Keeperman, Yinzhi Lai, Dimana Miteva, Tracy Krimmel, Barkha Aggarwal, David Valcarcel, Pierre Fenaux, Jake Shortt, Uwe Platzbecker, Guillermo Garcia-Manero, Amer Zeidan
Institutions: University of Florence, IRCCS Humanitas Research Hospital, Moffitt Cancer Center, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Switzerland), Vall d'Hebron Hospital Universitari, Hôpital Saint-Louis, Université Paris Diderot, Monash Health, Monash University, University Hospital Leipzig, The University of Texas MD Anderson Cancer Center, Yale University
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4417011660
Cites:
Cited by: 1
Related to: